DOCSLIB.ORG

University Microfilms International 300 N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

8214146 Snider, Ray Michael AMPHETAMINE AND METHYLPHENIDATE EFFECTS ON NEUROMUSCULAR TRANSMISSION IN THE RAT PHRENIC NERVE - DIAPHRAGM PREPARATION: MECHANISTIC STUDIES CORRELATING MUSCLE CONTRACTION, BIOCHEMICAL AND ELECTROPHYSIOLOGICAL RESULTS The Ohio State University PH.D. 1982 University Microfilms International 300 N. Zeeb Road. Ann Arbor, M I 48106 PLEASE NOTE: In all cases this material has been filmed in the best possible way from the available copy. Problems encountered with this document have been identified here with a check mark V . 1. Glossy photographs or pages ^ 2. Colored illustrations, paper or print _____ 3. Photographs with dark background. 4. Illustrations are poor copy______ 5. Pages with black marks, not original copy ___ 6. Print shows through as there is text on both sides of page _____ 7. Indistinct, broken or small print on several pages _____ 8. Print exceeds margin requirements _____ 9. Tightly bound copy with print lost in spine _____ 10. Computer printout pages with indistinct print ______ 11. Page(s) ___________lacking when material received, and not available from school or author. 12. Page(s) ___________seem to be missing in numbering only as text follows. 13. Two pages numbered ___________. Text follows. 14. Curling and wrinkled pages______ 15. Other _________________________________________________________________ University Microfilms International AMPHETAMINE AND METHYLPHENIDATE EFFECTS ON NEUROMUSCULAR TRANSMISSION IN THE RAT PHRENIC NERVE-DIAPHRAGM PREPARATION: MECHANISTIC STUDIES CORRELATING MUSCLE CONTRACTION, BIOCHEMICAL AND ELECTROPHYSIOLOGICAL RESULTS DISSERTATION. Presented in P a rtia l Fu lfillm en t o f the Requirements for the Degree Doctor of Philosophy in the Graduate School o f The Ohio State University By Ray Michael Snider; B.A. ***** The Ohio State University 1982 Reading Committee: Approved By Michael C. Gerald Dennis R. F e lle r Norman J. Uretsky Adviser Lane J. Wallace College o f Pharmacy ACKNOWLEDGEMENTS To Mary Ellen and my parents, Robert and Dorothy, whose - loving devotion and encouragement has been a source of strength to me, and to who I owe a great deal. To Dr. Michael C. Gerald with whom I have shared a productive, professional relationship and who has been profoundly instrumental in shaping my career. To the Faculty o f the Division of Pharmacology. I dedicate this work to Dr. Lauren K. Gerbrandt; without his influence on my l i f e I would not be where I am today. VITA December 28, 1948 ......................... Born - Los Angeles, Calif. 1974 .................................................... B.A. in Psychology, C alifornia State University Northridge, Northridge, California 1974-1975 ......................................... Technician in the Psychobiology Research Laboratory, V.A. Hospital, Sepulveda, California 1975-1976 ......................................... Teaching Assistant, Department of Psychology, California State University Northridge, Northridge, C alifornia 1976-1981 ......................................... Research Assistant, College of Pharmacy, The Ohio State U niversity, Columbus, Ohio PUBLICATIONS Gerbrandt, L.K., Weyand, T.G. and Snider, R.M.: Afferent control o f hippocampal theta rhythms. Soc. Neurosci. Abstr. JL_: 548, 1975. Gerald, M.C., Gupta, T.K. and Snider, R.M.: Tolerance to amphetamine- induced impairment o f rotarod performance in rats . Psychopharmacology 61: 317-318, 1979. Snider, R.M. and Gerald, M.C.: Electrophysiological analysis of (+)-amphetamine effects on neuromuscular transmission in the rat. Pharmacologist 22: 165, 1980. Snider, R.M., Meldrum, M.J. and Gerald, M.C.: Effects of methyl- phenidate on neuromuscular transmission and muscle contraction in v it r o . Fed. Proc. 4(h 278, 1981. Gerald, M.C. and Snider, R.M.: Amphetamine effects on muscle contraction in the incannulated rat phrenic nerve-diaphragm preparation. Fed. Proc. 40: 278, 1981. i i i Snider, R.M. and Gerald, M.C.: Amphetamine effects on acetylcholine release and mammalian neuromuscular transmission. L ife Sci. 29: 1661-1668, 1981. Snider, R.M. and Gerald, M.C.: Amphetamine increases acetylcholine release from the phrenic nerve: Evidence fo r a noradrenergic- mediated response. Soc. Neurosci. Abstr. 7_: 795, 1981. Meldrum, M .J ., Snider, R.M. and Gerald, M.C.: Cholinergic- independent effects of amphetamine on mammalian skeletal muscle contractions. Neuropharmacology, in press. Snider, R.M. and Gerald, M.C.: Studies on the mechanism of (+)- amphetamine enhancement o f neuromuscular transmission: Muscle contraction, electrophysiological, and biochemical studies. J. Pharmacol. Exp. Ther., submitted fo r publication, 1981. Gerald, M.C. and Snider, R.M.: -Adrenoceptor enhancement of acetylcholine release from motor nerves and effects on muscle contractions by amphetamine and norepinephrine. Fed. Proc., submitted for publication, 1981. FIELDS OF STUDY Major Field: Pharmacology Neuropharmacology Neurobiology Neuromuscular Junction Pharmacology Professor, Michael C. Gerald TABLE OF CONTENTS Page ACKNOWLEDGEMENTS. .................................................................................. i i VITA.................................................................................................................. i i i LIST OF TABLES............................................................................................. ix LIST OF FIGURES......................................................................................... x ii Chapter I . INTRODUCTION .................................................................................. 1 Overview ...................................................................................... 1 Physiology o f Neuromuscular Transmission and Muscle Contraction .......................................................... 3 Neuromuscular transmission ..................................... 3 ACh synthesis .............................................................. 9 ACh storage .................................................................. 10 ACh release ...................................................... 11 Methodological considerations ............................. 12 Termination of ACh action ..................................... 18 Muscle contraction ..................................................... 19 Pharmacology o f Neuromuscular Transmission ................. 23 Presynaptic Effects .............................................................. 24 Hemicholinium and related compounds that inhibit ACh synthesis ......................................... 24 Agents which in h ib it the release o f ACh . 24 Agents which enhance the release o f ACh . 25 Postsynaptic Effects .............................................................. 27 Competitive antagonists ......................................... 27 Noncompetitive or depolarizing blockers . 30 Agents which enhance postsynpatic effects o f A C h...................................................................... 31 Amphetamine Effects on Physical Performance in Humans .................................................................................. 32 Overview .......................................................................... 32 Laboratory studies of amphetamine's effects on physical performance in humans ................. 33 v Page Amphetamine Effects on Physical Performance in Laboratory Animals.......................................................... 39 Enhancement o f performance ................................. 40 Impairment of performance ..................................... 41 Amphetamine Effects on Isolated Mammalian Skeletal Muscle .................................................................................. 42 Amphetamine Effects on D irectly Stimulated Muscle Contractions ...................................................................... 52 Neuropharmacological Mechanism o f Amphetamine Action.................................................................................. 53 Adrenergic Mechanisms ......................................................... 53 Release o f catecholamines ....................... 54 Inhibition of reuptake ' ............................ 54 In h ib itio n of monoamine oxidase (MAO). 55 Direct adrenoceptor effects ................................. 55 Amphetamine Effects on Cholinergic Systems .... 55 Effects on autonomic ganglia ............................. 55 Effects on CNS preparations ................... 57 Adrenergic-Cholinergic Interactions ............................. 57 Adrenergic effects on neuromuscular transmission .......................................................... 58 Adrenergic effects on autonomic and central nervous system cholinergic preparations . 62 Mechanisms of NE effects on ACh release. 65 Methyl pheni date ...................................................................... 67 Neuropharmacology o f methylphenidate .... 67 Methylphenidate, performance and neuro­ muscular transmission ..................................... 69 STATEMENT OF THE PROBLEM...................................................................... 72 Chapter I I . MATERIALS AND METHODS.............................................................. 76 Animals ...................................................................................... 76 Muscle Contraction Studies ............................................. 76 General procedure ..................................................... 76 Electrophysiological Studies ......................................... 84 Biochemical
Recommended publications
  • Long-Lasting Analgesic Effect of the Psychedelic Drug Changa: a Case Report

    Long-Lasting Analgesic Effect of the Psychedelic Drug Changa: a Case Report

    CASE REPORT Journal of Psychedelic Studies 3(1), pp. 7–13 (2019) DOI: 10.1556/2054.2019.001 First published online February 12, 2019 Long-lasting analgesic effect of the psychedelic drug changa: A case report GENÍS ONA1* and SEBASTIÁN TRONCOSO2 1Department of Anthropology, Philosophy and Social Work, Universitat Rovira i Virgili, Tarragona, Spain 2Independent Researcher (Received: August 23, 2018; accepted: January 8, 2019) Background and aims: Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa,a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods: We describe the case and offer a brief review of supportive findings. Results: A long-lasting analgesic effect after the use of changa was reported. Possible analgesic mechanisms are discussed. We suggest that both pharmacological and non-pharmacological factors could be involved. Conclusion: These findings offer preliminary evidence of the analgesic effect of changa, but due to its complex pharmacological actions, involving many neurotransmitter systems, further research is needed in order to establish the specific mechanisms at work. Keywords: analgesic, pain, psychedelic, psychoactive, DMT, β-carboline alkaloids INTRODUCTION effects of ayahuasca usually last between 3 and 5 hr (McKenna & Riba, 2015), but the effects of smoked changa – The treatment of pain is one of the most significant chal- last about 15 30 min (Ott, 1994). lenges in the history of medicine. At present, there are still many challenges that hamper pain’s appropriate treatment, as recently stated by American Pain Society (Gereau et al., CASE DESCRIPTION 2014).
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics

    Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics

    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
  • (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact

    (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact

    pharmaceuticals Review Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Andreia Machado Brito-da-Costa 1 , Diana Dias-da-Silva 1,2,* , Nelson G. M. Gomes 1,3 , Ricardo Jorge Dinis-Oliveira 1,2,4,* and Áurea Madureira-Carvalho 1,3 1 Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal; [email protected] (A.M.B.-d.-C.); ngomes@ff.up.pt (N.G.M.G.); [email protected] (Á.M.-C.) 2 UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 3 LAQV-REQUIMTE, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 4 Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal * Correspondence: [email protected] (D.D.-d.-S.); [email protected] (R.J.D.-O.); Tel.: +351-224-157-216 (R.J.D.-O.) Received: 21 September 2020; Accepted: 20 October 2020; Published: 23 October 2020 Abstract: Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids.
  • Downloaded for Personal Non-Commercial Research Or Study, Without Prior Permission Or Charge

    Downloaded for Personal Non-Commercial Research Or Study, Without Prior Permission Or Charge

    https://theses.gla.ac.uk/ Theses Digitisation: https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ This is a digitised version of the original print thesis. Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] STUDIES OU THE MODE OF ACTION OF QUATERNARY AMMONIUM COMPOUNDS WITH MUSCLE RELAXANT AND OTHER PHARMACOLOGICAL ACTIVITIES A Thesis submitted to the University of Glasgow in candidature for the degree of Doctor of Philosophy in the Faculty of Medicine *y Thomas C. Muir, B.Sc., M.P.S. Division of Experimental Pharmacology, Institute of Physiology, The University, Glasgow. March 1962. ProQuest Number: 10656287 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10656287 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
  • B Ramamohima R

    B Ramamohima R

    I I CYTOPROTECTIVE ACTIONS PF NICOTINE: THE INCREASED EXPRESSION OF a.7 NICOTINIC RECEPTORS AND NGF/TrkA RECEPTORS ' . ' f !'b y' Ramamohima R. Jonnala ' ' ' I' Submitted to the Faculty o~the School of Graduate Studies of Medical College of Georgia in Partial Fulfillment of the Requirements of the Degree of Doctor of Philosophy Juiy, 2001 I' l Cytoprotective Actions of Nicotine: The Increased Expression of a.7 Nicotinic Receptors a-!ld NGF/TrkA Receptors This dissertation is submitted by Ramamohana R. Jonnala and has been examined and approved by an appointed committee of the faculty of the school of Graduate Studies of the Medical College of Georgia. The signatures which appear below verify the fact that all required changes have been incorporated and that the dissertation has received final approval with reference to content, form and accuracy of presentation. ' This dissertation is therefore in partial fulfillment of the requirements of the degree of Doctor of Philosophy. ACKNOWLEDGMENTS I would like to extend my appreciation to my major advisor, Dr. Jerry J. Buccafusco, for his guidance, encouragement and support. I would also like to thank my committee members, Dr. Alvin V. Terry Jr., Dr. William D. Hill, Dr. Nevin A. Lambert and Dr. Clare M. Bergson and also my thesis readers Dr. Debra Gearhart and Dr. Dale W. Sickles for their time and valuable suggestions. My sincere thanks to Dr. Deborah L. Lewis, Dr. Robert W. Caldwell and Dr. Gary C. Bond for encouraging me to enter the graduate program in the Department of Pharmacology & Toxicology, Medical College of Georgia. My sincere thanks to members of my laboratory Laura, Vanessa, Daniel, Cat, Mark, Nandu, Lu, and Shyamala for their assistance and suggestions.
  • PAPER Monoamine Oxidase Inhibition Is Unlikely to Be Relevant To

    PAPER Monoamine Oxidase Inhibition Is Unlikely to Be Relevant To

    International Journal of Obesity (2001) 25, 1454–1458 ß 2001 Nature Publishing Group All rights reserved 0307–0565/01 $15.00 www.nature.com/ijo PAPER Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release{ IC Kilpatrick1*, M Traut2 and DJ Heal1 1Knoll Limited Research and Development, Nottingham, UK; and 2Knoll GmbH, 50 Knollstrasse, D-67061, Ludwigshafen, Germany OBJECTIVE AND DESIGN: It has been proposed that the anti-obesity agent, phentermine, may act in part via inhibition of monoamine oxidase (MAO). The ability of phentermine to inhibit both MAOA and MAOB in vitro has been examined along with that of the fenfluramine isomers, a range of selective serotonin reuptake inhibitors and sibutramine and its active metabolites. RESULTS: In rat brain, harmaline and lazabemide showed potent and selective inhibition of MAOA and MAOB, their respective target enzymes, with IC50 values of 2.3 and 18 nM. In contrast, all other drugs examined were only weak inhibitors of MAOA and MAOB with IC50 values for each enzyme in the moderate to high micromolar range. For MAOA, the IC50 for phentermine was estimated to be 143 mM, that for S( þ )-fenfluramine, 265 mM and that for sertraline, 31 mM. For MAOB, example IC50s were as follows: phentermine (285 mM), S( þ )-fenfluramine (800 mM) and paroxetine (16 mM). Sibutramine was unable to inhibit either enzyme, even at its limit of solubility. CONCLUSION: We therefore suggest that MAO inhibition is unlikely to play a role in the pharmacodynamic properties of any of the tested drugs, including phentermine.
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss

    Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss

    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
  • Chemical Composition of Traditional and Analog Ayahuasca

    Chemical Composition of Traditional and Analog Ayahuasca

    Journal of Psychoactive Drugs ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ujpd20 Chemical Composition of Traditional and Analog Ayahuasca Helle Kaasik , Rita C. Z. Souza , Flávia S. Zandonadi , Luís Fernando Tófoli & Alessandra Sussulini To cite this article: Helle Kaasik , Rita C. Z. Souza , Flávia S. Zandonadi , Luís Fernando Tófoli & Alessandra Sussulini (2020): Chemical Composition of Traditional and Analog Ayahuasca, Journal of Psychoactive Drugs, DOI: 10.1080/02791072.2020.1815911 To link to this article: https://doi.org/10.1080/02791072.2020.1815911 View supplementary material Published online: 08 Sep 2020. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ujpd20 JOURNAL OF PSYCHOACTIVE DRUGS https://doi.org/10.1080/02791072.2020.1815911 Chemical Composition of Traditional and Analog Ayahuasca Helle Kaasik a, Rita C. Z. Souzab, Flávia S. Zandonadib, Luís Fernando Tófoli c, and Alessandra Sussulinib aSchool of Theology and Religious Studies; and Institute of Physics, University of Tartu, Tartu, Estonia; bLaboratory of Bioanalytics and Integrated Omics (LaBIOmics), Institute of Chemistry, University of Campinas (UNICAMP), Campinas, SP, Brazil; cInterdisciplinary Cooperation for Ayahuasca Research and Outreach (ICARO), School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil ABSTRACT ARTICLE HISTORY Traditional ayahuasca can be defined as a brew made from Amazonian vine Banisteriopsis caapi and Received 17 April 2020 Amazonian admixture plants. Ayahuasca is used by indigenous groups in Amazonia, as a sacrament Accepted 6 July 2020 in syncretic Brazilian religions, and in healing and spiritual ceremonies internationally.
  • Journal of Pharmacy and Pharmacology 1962 Volume.14 Suppl

    Journal of Pharmacy and Pharmacology 1962 Volume.14 Suppl

    BRITISH PHARMACEUTICAL CONFERENCE NINETY-NINTH ANNUAL MEETING, LIVERPOOL, 1962 REPORT OF PROCEEDINGS OFFICERS: President: Miss M. A. Bu rr, M.P.S., Nottingham Chairman: J. C. H anbury, M.A., B.Pharm., F.P.S., F.R.I.C. Vice-Chairmen: R. R . Bennett, B.Sc., F.P.S., F.R.I.C., Eastbourne. H . D eane, B.Sc., F.P.S., F.R.I.C., Sudbury. H . H umphreys Jones, F.P.S., F.R.I.C., Liverpool. T. E. W allis, D .S c., F.P.S., F.R.I.C., F.L.S., London. H . Brindle, M .Sc., F.P.S., F.R.I.C., Altrincham. N. Evers, B.Sc., Ph.D., F.R.I.C., Ware. A. D . P ow ell, M.P.S., F.R.I.C., Nottingham. H. Berry, B.Sc., Dip.Bact. (Lond.), F.P.S., F.R.I.C., Eastbourne. H . B. M ackie, B.Pharm., F.P.S., Brighton. G. R. Boyes, L.M.S.S.A., B.Sc., F.P.S., F.R.I.C., London. H . D avis, C.B.E., B.Sc., Ph.D., F.P.S., F.R.I.C., London. J. P. T o dd , Ph.D., F.P.S., F.R.I.C., Glasgow. K. Bullock, M .Sc., Ph.D., F.P.S., F.R.I.C., Manchester. F. H artley, B.Sc., Ph.D., F.P.S., F.R.I.C., London. G. E. F oster, B.Sc., Ph.D., F.R.I.C., Dartford. H . T reves Bro w n , B.Sc., F.P.S., London.
  • 5/1 (2005) 41 - 4541

    5/1 (2005) 41 - 4541

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by idUS. Depósito de Investigación Universidad de Sevilla Vol. 5/1 (2005) 41 - 4541 JOURNAL OF NATURAL REMEDIES Cytotoxic activity of methanolic extract and two alkaloids extracted from seeds of Peganum harmala L. Hicham Berrougui1,2*, Miguel López-Lázaro1, Carmen Martin-Cordero1, Mohamed Mamouchi2, Abdelkader Ettaib2, Maria Dolores Herrera1. 1. Department of Pharmacology School of Pharmacy. Séville, Spain. 2. School of Medicine and Pharmacy, UFR (Natural Substances), Rabat, Morocco. Abstract Objective: To study the cytotoxic activity of P. harmala. Materials and method: The alkaloids harmine and harmaline have been isolated from a methanolic extract from the seeds of P. harmala L. and have been characterized by spectroscopic-Mass and NMR methods. The cytotoxicity of the methanolic extract and both alkaloids has been investigated in the three human cancer cell lines UACC-62 (melanoma), TK- 10 (renal) and MCF-7 (breast) and then compared to the positive control effect of the etoposide. Results and conclusion: The methanolic extract and both alkaloids have inhibited the growth of these three cancer cell-lines and we have discussed possible mechanisms involved in their cytotoxicity. Keywords: Peganum harmala, harmine, harmaline, cytotoxicity, TK-10, MCF-7, UACC-62. 1. Introduction Peganum harmala L. (Zygophyllaceae), the so- convulsive or anticonvulsive actions and called harmal, grows spontaneously in binding to various receptors including 5-HT uncultivated and steppes areas in semiarid and receptors and the benzodiazepine binding site pre-deserted regions in south Spain and South- of GABAA receptors [10]. In addition, these East Morocco [1].
  • Metabolic Pathways of the Psychotropic-Carboline Alkaloids, Harmaline and Harmine, by Liquid Chromatography/Mass Spectrometry and NMR Spectroscopy

    Metabolic Pathways of the Psychotropic-Carboline Alkaloids, Harmaline and Harmine, by Liquid Chromatography/Mass Spectrometry and NMR Spectroscopy

    Food Chemistry 134 (2012) 1096–1105 Contents lists available at SciVerse ScienceDirect Food Chemistry journal homepage: www.elsevier.com/locate/foodchem Metabolic pathways of the psychotropic-carboline alkaloids, harmaline and harmine, by liquid chromatography/mass spectrometry and NMR spectroscopy Ting Zhao a, Shan-Song Zheng a, Bin-Feng Zhang a,b,c, Yuan-Yuan Li a, S.W. Annie Bligh d, ⇑ ⇑ Chang-Hong Wang a,b,c, , Zheng-Tao Wang a,b,c, a Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201210, China b The MOE Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, 1200 Cailun Road, Shanghai 201210, China c Shanghai R&D Center for Standardization of Chinese Medicines, 199 Guoshoujing Road, Shanghai 201210, China d Institute for Health Research and Policy, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK article info abstract Article history: The b-carboline alkaloids, harmaline and harmine, are present in hallucinogenic plants Ayahuasca and Received 3 June 2011 Peganum harmala, and in a variety of foods. In order to establish the metabolic pathway and bioactivities Received in revised form 25 January 2012 of endogenous and xenobiotic bioactive b-carbolines, high-performance liquid chromatography, coupled Accepted 6 March 2012 with mass spectrometry, was used to identify these metabolites in human liver microsomes (HLMs) Available online 16 March 2012 in vitro and in rat urine and bile samples after oral administration of the alkaloids. Three metabolites of harmaline and two of harmine were found in the HLMs.
  • INTRODUCTION One of the Tasks of a Pharmacologist Is the Classification of Drugs

    INTRODUCTION One of the Tasks of a Pharmacologist Is the Classification of Drugs

    NEUROPSYCHOPHARMACOLOGIC STUDIES OF MARIJUANA: SOME SYNTHETIC AND NATURAL THC DERIVATIVES IN ANIMALS AND MAN* Edward F. Domino Department of Pharmacology, University of Michigan, Ann Arbor 48104 and Lafayette Clinic, Detroit, Mich. 48207 INTRODUCTION One of the tasks of a pharmacologist is the classification of drugs. Marijuana and its derivatives pose some problems. Legally marijuana has been classified as a narcotic, yet pharmacologically it is quite different. Mankind has known about the Cannabis plant from which marijuana and other products are obtained for more than 4,708 years. A considerable body of data is available to describe its gross effects. Over the centuries it has been called a depressant, euphoriant, ine- briant, intoxicant, hallucinogen, psychotomimetic, sedative-hypnotic-anesthetic, and stimulant. Perhaps more than any other drug it is a social irritant that elicits rather remarkable behavior reactions in both users and nonusers. Moreau’ in 1845, employed it to produce a model psychosis, thus initiating the fashion to study hallucinogens as a means of gaining insights into mental illness. Lewin2 classified Cannabis as one of the “phantastica: hallucinating substances.” One text on hallucinogens3 does not even refer to Cannabis, but another does? There are some aspects of the subjective effects of both LSD-25 and Cannabis that are similar, yet the latter produces sedative effects, no significant sympatho- mimetic actions, and no cross-tolerance to LSD-25. Hollister5 reviewed the re- cent findings on the effects in man of marijuana and its putative active ingredient Ag-THC, stressing that current investigators have, for the most part, confirmed the Cannabis-induced clinical syndromes long known to occur.